Mary McFarlane

631 total citations
6 papers, 334 citations indexed

About

Mary McFarlane is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mary McFarlane has authored 6 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mary McFarlane's work include Monoclonal and Polyclonal Antibodies Research (2 papers), Glycosylation and Glycoproteins Research (1 paper) and Synthesis and pharmacology of benzodiazepine derivatives (1 paper). Mary McFarlane is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (2 papers), Glycosylation and Glycoproteins Research (1 paper) and Synthesis and pharmacology of benzodiazepine derivatives (1 paper). Mary McFarlane collaborates with scholars based in United Kingdom, Sweden and United States. Mary McFarlane's co-authors include Jacintha Shenton, Lolke de Haan, Simon J. Henderson, Nicholas Buss, Maria Groves, Keith Tan, Kina Höglund, Rajesh Narwal, Anna Bogstedt and Andy Billinton and has published in prestigious journals such as Cancer Research, Molecular Cancer Therapeutics and Journal of Alzheimer s Disease.

In The Last Decade

Mary McFarlane

6 papers receiving 329 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary McFarlane United Kingdom	4	190	187	71	51	37	6	334
Grzegorz Kijanka Netherlands	10	221 1.2×	171 0.9×	126 1.8×	31 0.6×	34 0.9×	11	338
Sofia Castelli United States	7	161 0.8×	103 0.6×	107 1.5×	138 2.7×	34 0.9×	11	355
Dante J. Merlino United States	10	111 0.6×	111 0.6×	55 0.8×	100 2.0×	41 1.1×	19	379
Robert Weik Austria	11	367 1.9×	156 0.8×	73 1.0×	22 0.4×	46 1.2×	13	492
Amanda Anderson United States	8	237 1.2×	42 0.2×	94 1.3×	152 3.0×	39 1.1×	21	493
Guillaume Brachet France	10	91 0.5×	66 0.4×	103 1.5×	26 0.5×	20 0.5×	13	314
Wenju Liu China	11	148 0.8×	66 0.4×	26 0.4×	108 2.1×	70 1.9×	37	510
Erik Vernet Denmark	9	278 1.5×	65 0.3×	44 0.6×	51 1.0×	9 0.2×	17	405
Raphaël Boisgard France	8	92 0.5×	115 0.6×	35 0.5×	39 0.8×	116 3.1×	12	356
Christopher C. Frye United States	11	638 3.4×	162 0.9×	29 0.4×	74 1.5×	54 1.5×	19	685

Countries citing papers authored by Mary McFarlane

Since Specialization

Citations

This map shows the geographic impact of Mary McFarlane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary McFarlane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary McFarlane more than expected).

Fields of papers citing papers by Mary McFarlane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary McFarlane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary McFarlane. The network helps show where Mary McFarlane may publish in the future.

Co-authorship network of co-authors of Mary McFarlane

This figure shows the co-authorship network connecting the top 25 collaborators of Mary McFarlane. A scholar is included among the top collaborators of Mary McFarlane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary McFarlane. Mary McFarlane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Lua, Ingrid, Jeff Chen, Kévin Contrepois, et al.. (2024). Abstract LB417: Leveraging advanced human lung models to explore mechanisms underlying T-DXd-associated interstitial lung disease (ILD). Cancer Research. 84(7_Supplement). LB417–LB417. 1 indexed citations

2.

Gregson, Stephen J., Neki V. Patel, Balakumar Vijayakrishnan, et al.. (2022). Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer. Molecular Cancer Therapeutics. 21(9). 1439–1448. 4 indexed citations

3.

Billinton, Andy, Philip M. Newton, Chris J. Lloyd, et al.. (2017). [P1–074]: PRECLINICAL DISCOVERY AND DEVELOPMENT OF MEDI1814, A MONOCLONAL ANTIBODY SELECTIVELY TARGETING BETA‐AMYLOID 42 (Aβ42). Alzheimer s & Dementia. 13(7S_Part_5). 9 indexed citations

4.

Bogstedt, Anna, Maria Groves, Keith Tan, et al.. (2015). Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies. Journal of Alzheimer s Disease. 46(4). 1091–1101. 4 indexed citations

5.

Buss, Nicholas, Simon J. Henderson, Mary McFarlane, Jacintha Shenton, & Lolke de Haan. (2012). Monoclonal antibody therapeutics: history and future. Current Opinion in Pharmacology. 12(5). 615–622. 315 indexed citations

6.

Bolton, Sarah, Wolfgang Brück, Jeffrey K. Huang, et al.. (2012). Anti-inflammatory Disease Therapies. Toxicologic Pathology. 40(1). 122–125. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact